Paralleling this approach, transposon-based delivery of NICD and Cre-recombinase into genetically engineered mice harboring the latent mutant Kras allele (KrasLSL-G12D) gave rise to liver tumors closely resembling human CCA by 8 weeks post-transfection [17]. The gene discussed is KRAS; the disease is cholangiocarcinoma.